NCT07030478尚未招募1 期
A Phase I/IIa Study to Evaluate the Safety and Tolerability of Monoclonal Antibody EP0089 in Patients With Advanced Solid Tumours
Ellipses Pharma0 个研究点目标入组 190 人开始时间: 2025年9月1日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 190
- 主要终点
- Safety and Tolerability of EP0089
研究概览
简要总结
This is a first-in-human (FIH), first-in-class, Phase I/IIa, open-label study designed to evaluate the safety and tolerability of EP0089 (study drug). Study drug will initially be given via intravenous (IV) infusion once every 2 weeks (Q2W), with one treatment cycle defined as 14 days. The study will enroll patients with advanced solid tumours for whom no standard therapy exists or for whom standard therapy has failed. An independent Safety Monitoring Committee (SMC) will review safety data at regular intervals to ensure participant safety and support dose escalation decisions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
N/A - is an open label study
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Applicable to all patients:
- •Must be ≥18 years of age (≥19 in South Korea) with documented recurrent, metastatic or unresectable solid tumours for whom no standard therapy exists or standard therapy has failed
- •ECOG performance status of 0 or 1 and life expectancy >3 months at screening
- •Ability to understand and provide written informed consent
- •Must be willing to comply with necessary contraceptive methods as required
- •Willing and able to comply with the scheduled study treatment plan, laboratory tests, and other study procedures.
- •Adequate hepatic, haematological and renal function as assessed by protocol-defined criteria.
- •Additional cohort/disease specific criteria apply
- •Measurable disease per RECIST v1.1
排除标准
- •Known active CNS metastases and/or leptomeningeal disease and/or carcinomatous meningitis.
- •Recent major surgery
- •Recent live or live-attenuated vaccine ≤ 30 days prior to the first dose
- •Current active, or history of, autoimmune disease that requires or required systemic treatment (ie, with disease modifying agents, corticosteroids, or immunosuppressive drugs) within 2 years prior to starting study treatment.
- •Prior severe hypersensitivity reaction to mAbs
- •Previous > Grade 2 peripheral neuropathy.
- •Significant neurological condition eg stroke, transient ischaemic attack (in the last 12 months), epilepsy, head trauma, brain surgery or prior history of any significant psychiatric disorder
- •Current active, or history of, autoimmune disease that requires or required continuous treatment within 2 years prior to starting study treatment
- •Receiving chronic systemic steroid therapy (> 10 mg /day of prednisone or equivalent) or any other form of immunosuppressive therapy ≤ 7 days prior the first dose of study drug. Topical or inhaled steroids are permitted.
- •Any prior immune-mediated or immune-related adverse events related to treatment with immune-modulatory agents that caused permanent discontinuation of the agent, that were ≥ Grade 3 in severity or in the opinion of the Investigator would otherwise jeopardise patient safety in this study.
- •One or more clinically significant (ie, active) cardiovascular diseases, myocardial infarction, or unstable angina (≤ 6 months prior to first administration of study drug)
研究组 & 干预措施
Dose Escalation
Experimental
3+3 design evaluating the safety and efficacy of EP0089
干预措施: EP0089-101 (Drug)
结局指标
主要结局
Safety and Tolerability of EP0089
时间窗: 126 weeks
The study's main goal is to find the highest safe dose of EP0089 and the best dose for future testing.
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
Safety and Efficacy of BA1302 in Patients With Advanced Solid TumorsPancreatic AdenocarcinomaBreast CancerMelanomaNon-Small Cell Lung CancerNCT06596915Shandong Boan Biotechnology Co., Ltd167
Enrolling By Invitation
1 期
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsNCT06115642Shanghai Henlius Biotech367
招募中
1 期
A Study of HLX42 in Advanced/Metastatic Solid TumorsNCT06210815Shanghai Henlius Biotech102
招募中
1 期
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309Advanced or Metastatic Solid TumorsNCT05957081PharmAbcine67
终止
1 期
A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsAdvanced Solid TumorsHematologic MalignanciesMultiple MyelomaLymphomaNCT04214093AstraZeneca9